These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 10235445

  • 1. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
    Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fedi S, Giusti B, Brunelli T, Giusti B, Brunelli T, Comeglio P, Gensini GF, Neri Serneri GG.
    Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
    [Abstract] [Full Text] [Related]

  • 2. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG.
    Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
    [Abstract] [Full Text] [Related]

  • 3. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H.
    Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
    [Abstract] [Full Text] [Related]

  • 4. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
    Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordøy A.
    Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
    [Abstract] [Full Text] [Related]

  • 5. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I, Wysokin Ski W, Karnicki K, Adamiec R.
    Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
    [Abstract] [Full Text] [Related]

  • 6. Long-term incubation with IL-4 and IL-10 oppositely modifies procoagulant activity of monocytes and modulates the surface expression of tissue factor and tissue factor pathway inhibitor.
    Paysant J, Soria C, Cornillet-Lefèbvre P, Nguyen P, Lenormand B, Mishal Z, Vannier JP, Vasse M.
    Br J Haematol; 2005 Nov; 131(3):356-65. PubMed ID: 16225656
    [Abstract] [Full Text] [Related]

  • 7. [Effects of tissue factor pathway inhibitor-1 on no-reflow in a rabbit model].
    Luo JG, Chen YD, Tian F, Wang CH, Lü Y, Yang XX, Lü SZ.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Dec; 37(12):1113-8. PubMed ID: 20193184
    [Abstract] [Full Text] [Related]

  • 8. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.
    Agledahl I, Brodin E, Svartberg J, Hansen JB.
    Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407
    [Abstract] [Full Text] [Related]

  • 9. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome.
    Amengual O, Atsumi T, Khamashta MA, Hughes GR.
    Thromb Haemost; 1998 Feb; 79(2):276-81. PubMed ID: 9493575
    [Abstract] [Full Text] [Related]

  • 10. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
    Mukherjee M, Ranlall N, Patel G, Rutlin A, Jehanli A, Kakkar VV.
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
    [Abstract] [Full Text] [Related]

  • 11. Parameters of the tissue factor pathway with coumadin/dipyridamole versus ticlopidine as adjunct antithrombotic-drug regimen in coronary artery stenting.
    Kopp CW, Steiner S, Priglinger U, Christ G, Probst P, Maurer G, Minar E, Huber K.
    Blood Coagul Fibrinolysis; 2003 Jun; 14(4):379-86. PubMed ID: 12945880
    [Abstract] [Full Text] [Related]

  • 12. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease.
    Eling M, Stephens AC, Oragui EE, Rivers RP, Levin M.
    Thromb Haemost; 2001 Feb; 85(2):240-4. PubMed ID: 11246540
    [Abstract] [Full Text] [Related]

  • 13. Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration.
    Cella G, Cipriani A, Tommasini A, Rampin E, Sbarai A, Rocconi R, Mazzaro G, Luzzatto G.
    Semin Thromb Hemost; 1997 Feb; 23(1):45-9. PubMed ID: 9156410
    [Abstract] [Full Text] [Related]

  • 14. [Tissue factor and tissue factor pathway inhibitor during specific bronchial challenge in allergic asthma patients].
    Kemona-Chetnik I, Bodzenta-Lukaszyk A, Kucharewicz I, Rogalewska AM.
    Przegl Lek; 2005 Feb; 62(2):98-101. PubMed ID: 16095153
    [Abstract] [Full Text] [Related]

  • 15. [Levels of plasma TF and TFPI activities in patients with acute leukemia].
    Zhu Y, Xie ZX, He XF, Han JZ, Li JC, He SL.
    Hunan Yi Ke Da Xue Xue Bao; 2000 Aug 28; 25(4):401-2, 405. PubMed ID: 12206017
    [Abstract] [Full Text] [Related]

  • 16. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.
    Naumnik B, Borawski J, Chyczewski L, Pawlak K, Mysliwiec M.
    Nephrol Dial Transplant; 2006 Dec 28; 21(12):3450-7. PubMed ID: 16982632
    [Abstract] [Full Text] [Related]

  • 17. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T, Gando S, Kemmotsu O, Mashio H, Goda Y, Kawahigashi H, Watanabe N.
    J Cardiothorac Vasc Anesth; 2001 Feb 28; 15(1):60-4. PubMed ID: 11254842
    [Abstract] [Full Text] [Related]

  • 18. Monocyte procoagulant activity induced by adherence to an artificial surface is reduced by end-point immobilized heparin-coating of the surface.
    Barstad RM, Hamers MJ, Møller AS, Sakariassen KS.
    Thromb Haemost; 1998 Feb 28; 79(2):302-5. PubMed ID: 9493580
    [Abstract] [Full Text] [Related]

  • 19. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD, Weitz JI, Yusuf S, Pogue J, Sussex B, Campeau J, Gill J, Schuld R, Joyner CD, Morris AL, Lai C, Théroux P, Marquis JF, Chan YK, Venkatesh G, Jessel A.
    Eur Heart J; 2000 Sep 28; 21(17):1473-81. PubMed ID: 10952840
    [Abstract] [Full Text] [Related]

  • 20. [Plasma tissue factor and tissue factor pathway inhibitor levels in acute myocardial infarction patients with no-reflow during percutaneous coronary intervention].
    Xu P, Qi XY, Li CH, Zhang JH, Liu DM, Liu J, Wang WL.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Nov 28; 36(11):1013-5. PubMed ID: 19102916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.